• / Free eNewsletters & Magazine
  • / My Account


  1. All
  2. Morningstar Articles
  1. The Benefits of Diversifying the Funding of a Gold Position

    Theravance THRX reported second-quarter earnings that matched our expectations, and we are keeping our fair value estimate at $29 per share. The company continues to make progress in each of its programs, namely the addition of a second Phase IIb compound in the Beyond Advair trials and completion ...

  2. An ETF for This Lagging Sector

    Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.

©2017 Morningstar Advisor. All right reserved.